Small molecule · Inhibitor of H+/K+ ATPase (gastric proton pump) (ATP4A) · developed by Phathom
Vonoprazan is a potassium-competitive acid blocker that concentrates in gastric parietal cells and reversibly binds the potassium-binding site of the H+/K+ ATPase proton pump, inhibiting the final step of gastric acid secretion. It is studied in symptomatic non-erosive gastroesophageal reflux disease.
Summary written with AI from the sources listed at the end of this page.
From the indications section of the FDA label (version of Jul 16, 2026). Read the full label for the exact wording, limitations and safety information.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07752407 | Phase 3 | Symptomatic Non-erosive Gastroesophageal Reflux Disease | Recruiting | PHAT |
| NCT06831344 | Phase 1 | Healthy Volunteers | Completed | PHAT |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Symptomatic Non-erosive Gastroesophageal Reflux DiseaseHealthy Volunteers
Updated Oct 25, 2026. Something wrong or missing? Report it on the PHAT page.
See PHAT's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
PHAT catalysts and pipeline →